<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1007">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05148039</url>
  </required_header>
  <id_info>
    <org_study_id>306930</org_study_id>
    <nct_id>NCT05148039</nct_id>
  </id_info>
  <brief_title>Comprehensive Assessment of Nutrition and Dietary Intervention in Hypermobile Ehlers Danlos Syndrome</brief_title>
  <acronym>CANDI-hEDS2</acronym>
  <official_title>Comprehensive Assessment of Nutrition &amp; Dietary Intervention in Hypermobile Ehlers Danlos Syndrome (hEDS/HSD): a Personalised Approach: Phase 2 &amp; 3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen Mary University of London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Queen Mary University of London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study involves a comprehensive nutritional assessment of hEDS participants who have&#xD;
      functional gastrointestinal disorders and dietary intervention to broaden their food choices&#xD;
      and nutritional intake.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The impact of diet on symptoms in patients with Hypermobile Ehlers Danlos Syndrome (hEDS/HSD)&#xD;
      is widely recognised yet poorly understood. The investigators aim is to assess existing&#xD;
      dietary patterns and nutritional status in hEDS/HSD as well as pilot a personalised dietary&#xD;
      strategy to optimise nutrition. Participants recruited from EDS UK and a tertiary&#xD;
      Neurogastroenterology clinic at the Royal London Hospital will undergo comprehensive&#xD;
      nutritional assessment and blood tests. The investigators will then undertake a feasibility&#xD;
      study of personalised dietary intervention in select cohort of patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 3, 2022</start_date>
  <completion_date type="Anticipated">October 3, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 3, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Tertiary clinic versus a selective community cohort</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients</measure>
    <time_frame>3 months</time_frame>
    <description>Number of patients who adhere to dietary recommendations based on acceptability of intervention and ease of delivery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>United Kingdom Diet Quality Index as calculated by the Scottish Collaborative Group Food Frequency Questionnaire (SCG FFQ)</measure>
    <time_frame>3 months</time_frame>
    <description>170- item semi-quantitative questionnaire, designed to assess the habitual diet of medium to large sized populations during the previous 3 months (higher score means better diet quality)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal Symptom Rating Scale (GSRS)</measure>
    <time_frame>3 months</time_frame>
    <description>13-item questionnaire assessing gastrointestinal symptoms across five domains (pain, bloating, constipation, diarrhoea and satiety) over a period of one week. (min:0 max: 7, higher score means worse symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety and Depression Scale (HADS)</measure>
    <time_frame>3 months</time_frame>
    <description>14-item scale assessing symptoms of either anxiety or depression (min: 0 max: 21, higher score means worse anxiety or depression)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visceral Sensitivity Index (VSI)</measure>
    <time_frame>3 months</time_frame>
    <description>15-item measurement of gastrointestinal-specific anxiety (min: 0 max: 75, higher score means worse gastrointestinal specific anxiety)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Health Questionnaire-15 (PHQ-15)</measure>
    <time_frame>3 months</time_frame>
    <description>15-item questionnaire to assess the domain of somatic symptoms (min: 0 max: 30, higher score means worse somatic symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Autonomic Symptom Score (COMPASS-31)</measure>
    <time_frame>3 months</time_frame>
    <description>31-item score to assess for symptoms of autonomic nervous system disturbance (min: 0 max 100, higher score means worse autonomic symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form 6D version 2 (SF-6Dv2)</measure>
    <time_frame>3 months</time_frame>
    <description>6-item questionnaire to assess impact of physical symptoms on daily functioning and quality of life (ranges from 1 (full health) to -0.574 (worst health); 0 (death))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resource Use Questionnaire</measure>
    <time_frame>3 months</time_frame>
    <description>16-item questionnaire to assess healthcare and health product utilisation over the preceding 3 months (no minimum / maximum, no score)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Hypermobile Ehlers-Danlos Syndrome</condition>
  <condition>Irritable Bowel Syndrome</condition>
  <condition>Functional Gastrointestinal Disorders</condition>
  <arm_group>
    <arm_group_label>Community cohort</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants from the Ehlers Danlos UK society community who low diet quality</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clinic cohort</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants from a Tertiary Neurogastroenterology clinic who have low die quality</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Dietician advice</intervention_name>
    <description>Personalised dietetic advice</description>
    <arm_group_label>Clinic cohort</arm_group_label>
    <arm_group_label>Community cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have completed Phase I of the CANDI-hEDS study&#xD;
&#xD;
          -  Diagnosis of hEDS / HSD according to physical examination and history taking&#xD;
&#xD;
          -  Diagnosis of Functional Dyspepsia and / or Irritable Bowel Syndrome according to Rome&#xD;
             IV criteria&#xD;
&#xD;
          -  Able and willing to give informed consent&#xD;
&#xD;
          -  Access to video conferencing and a smart phone device&#xD;
&#xD;
          -  Able to travel to the Wingate Institute&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Dependent upon artificial feeding (parenteral and enteral)&#xD;
&#xD;
          -  Structural gastrointestinal disease&#xD;
&#xD;
          -  Any chronic health condition which already requires a restricted diet e.g. diabetes&#xD;
             mellitus&#xD;
&#xD;
          -  Functional vomiting disorder with associated weight loss&#xD;
&#xD;
          -  Multiple Type I hypersensitivity reactions to food groups (i.e. anaphylaxis,&#xD;
             urticaria, respiratory symptoms or positive RAST tests).&#xD;
&#xD;
          -  Previous or current severe mental health disorder (e.g. severe depression with&#xD;
             suicidal ideation)&#xD;
&#xD;
          -  Previous or current eating disorder&#xD;
&#xD;
          -  Positive screen for avoidant restrictive food intake disorder (ARFID)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Queen Marys University London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Salvatore Vezza</last_name>
      <phone>44 (0)20 7882 6826</phone>
      <email>s.vezza@qmul.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Qasim Aziz</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rabia Topan</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 16, 2021</study_first_submitted>
  <study_first_submitted_qc>November 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2021</study_first_posted>
  <last_update_submitted>November 30, 2021</last_update_submitted>
  <last_update_submitted_qc>November 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nutrition</keyword>
  <keyword>Diet</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
    <mesh_term>Ehlers-Danlos Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

